SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
This Quarter Return
+7.71%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.21B
AUM Growth
+$1.21B
(-24%)
Cap. Flow
-$442M
Cap. Flow
% of AUM
-36.55%
Top 10 Holdings %
Top 10 Hldgs %
62.3%
Holding
87
New
11
Increased
22
Reduced
15
Closed
26
Top Buys
| 1 |
BIOA
BioAge Labs, Inc. Common Stock
BIOA
|
$47.9M |
| 2 |
Incyte
INCY
|
$47.2M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
$21M |
| 4 |
IDEAYA Biosciences
IDYA
|
$18.9M |
| 5 |
Rhythm Pharmaceuticals
RYTM
|
$14.5M |
Top Sells
| 1 |
Ascendis Pharma
ASND
|
$100M |
| 2 |
Stryker
SYK
|
$65.7M |
| 3 |
Align Technology
ALGN
|
$52.8M |
| 4 |
Intuitive Surgical
ISRG
|
$38.8M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$35.9M |
Sector Composition
| 1 | Healthcare | 99.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Natera
NTRA
$23.1B
| $197M | 15.62% | 1,550,280 | – | – |
|
2
Vera Therapeutics
VERA
$1.38B
| $123M | 9.8% | 2,793,987 | – | – |
|
3
Novo Nordisk
NVO
$251B
| $86.5M | 6.86% | 726,329 +76,788 | +12% | +$9.14M |
|
4
AstraZeneca
AZN
$248B
| $63.1M | 5% | 809,406 +7,989 | +1% | +$622K |
|
|
5
IDEAYA Biosciences
IDYA
$2.15B
| $55.4M | 4.4% | 1,749,455 +597,927 | +52% | +$18.9M |
|
6
Elanco Animal Health
ELAN
$9.12B
| $51.7M | 4.1% | 3,518,684 +654,434 | +23% | +$9.61M |
|
|
BIOA
7
BioAge Labs, Inc. Common Stock
BIOA
$177M
| $47.9M | 3.81% | +2,304,901 | New | +$47.9M |
|
|
8
Incyte
INCY
$16.5B
| $47.2M | 3.75% | +714,176 | New | +$47.2M |
|
|
RAPP
9
Rapport Therapeutics
RAPP
$643M
| $40.9M | 3.24% | 1,995,594 +44,032 | +2% | +$902K |
|
10
ArriVent BioPharma
AVBP
$776M
| $39.9M | 3.16% | 1,696,752 | – | – |
|
11
Axsome Therapeutics
AXSM
$6.05B
| $34.1M | 2.71% | 379,527 +69,329 | +22% | +$6.23M |
|
12
Soleno Therapeutics
SLNO
$3.6B
| $29.6M | 2.35% | 586,344 +31,985 | +6% | +$1.61M |
|
13
Y-mAbs Therapeutics
YMAB
$388M
| $28.9M | 2.29% | 2,194,278 | – | – |
|
14
Dyne Therapeutics
DYN
$1.92B
| $27.7M | 2.2% | 772,070 -853,633 | -53% | -$30.7M |
|
15
Cogent Biosciences
COGT
$1.69B
| $24.5M | 1.94% | 2,265,230 -508,056 | -18% | -$5.49M |
|
16
Savara
SVRA
$567M
| $24M | 1.91% | 5,662,550 +303,632 | +6% | +$1.29M |
|
|
INZY
17
DELISTED
Inozyme Pharma
INZY
| $22.4M | 1.78% | 4,280,308 | – | – |
|
|
18
Jazz Pharmaceuticals
JAZZ
$7.75B
| $21M | 1.67% | +188,562 | New | +$21M |
|
19
Insmed
INSM
$28.8B
| $20.9M | 1.66% | 286,307 +58,560 | +26% | +$4.27M |
|
20
Syndax Pharmaceuticals
SNDX
$1.41B
| $15.1M | 1.2% | 786,999 -1,366,670 | -63% | -$26.3M |
|
|
21
Rhythm Pharmaceuticals
RYTM
$6.85B
| $14.5M | 1.15% | +276,678 | New | +$14.5M |
|
22
Edwards Lifesciences
EW
$47.8B
| $13.4M | 1.06% | 202,898 -521,327 | -72% | -$34.4M |
|
23
Boston Scientific
BSX
$156B
| $11.4M | 0.9% | 135,819 -35,261 | -21% | -$2.95M |
|
24
Pharvaris
PHVS
$1.39B
| $11.1M | 0.88% | 600,302 -1,232 | -0.2% | -$22.8K |
|
25
Edgewise Therapeutics
EWTX
$1.51B
| $10.3M | 0.82% | 384,767 -90,924 | -19% | -$2.43M |
|